{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T21:37:04Z","timestamp":1787953024645,"version":"build-2784847793"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,1,15]],"date-time":"2018-01-15T00:00:00Z","timestamp":1515974400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2018,1,15]],"date-time":"2018-01-15T00:00:00Z","timestamp":1515974400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Pemetrexed is indicated for non-small cell lung carcinoma and mesothelioma, but often has limited efficacy due to drug resistance. To probe the molecular mechanisms underlying chemotherapeutic response, we performed mRNA and microRNA (miRNA) expression profiling of pemetrexed treated and untreated lymphoblastoid cell lines (LCLs) and applied a hierarchical Bayesian method. We identified genetic variation associated with gene expression in human lung tissue for the most significant differentially expressed genes (Benjamini-Hochberg [BH] adjusted p\u2009&lt;\u20090.05) using the Genotype-Tissue Expression data and found evidence for their clinical relevance using integrated molecular profiling and lung adenocarcinoma survival data from The Cancer Genome Atlas project. We identified 39 miRNAs with significant differential expression (BH adjusted p\u2009&lt;\u20090.05) in LCLs. We developed a gene expression based imputation model of drug sensitivity, quantified its prediction performance, and found a significant correlation of the imputed phenotype generated from expression data with survival time in lung adenocarcinoma patients. Differentially expressed genes (<jats:italic>MTHFD2<\/jats:italic> and <jats:italic>SUFU<\/jats:italic>) that are putative targets of differentially expressed miRNAs also showed differential perturbation in A549 fusion lung tumor cells with further replication in A549 cells. Our study suggests pemetrexed may be used in combination with agents that target miRNAs to increase its cytotoxicity.<\/jats:p>","DOI":"10.1038\/s41598-017-19004-3","type":"journal-article","created":{"date-parts":[[2018,1,9]],"date-time":"2018-01-09T11:46:02Z","timestamp":1515498362000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Gene and MicroRNA Perturbations of Cellular Response to Pemetrexed Implicate Biological Networks and Enable Imputation of Response in Lung Adenocarcinoma"],"prefix":"10.1038","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4204-8734","authenticated-orcid":false,"given":"Eric R.","family":"Gamazon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew R.","family":"Trendowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujia","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Wing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shannon M.","family":"Delaney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Won","family":"Huh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shan","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy J.","family":"Cox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1613-097X","authenticated-orcid":false,"given":"M. Eileen","family":"Dolan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,1,15]]},"reference":[{"key":"19004_CR1","doi-asserted-by":"publisher","first-page":"36","DOI":"10.3978\/j.issn.2218-6751.2014.05.01","volume":"4","author":"BA Chan","year":"2015","unstructured":"Chan, B. A. & Hughes, B. G. Targeted therapy for non-small cell lung cancer: current standards and the promise of the future. Transl Lung Cancer Res 4, 36\u201354, https:\/\/doi.org\/10.3978\/j.issn.2218-6751.2014.05.01 (2015).","journal-title":"Transl Lung Cancer Res"},{"key":"19004_CR2","doi-asserted-by":"publisher","first-page":"3204","DOI":"10.1200\/JCO.2015.66.3955","volume":"34","author":"F Dammeijer","year":"2016","unstructured":"Dammeijer, F. et al. Efficacy of Tumor Vaccines and Cellular Immunotherapies in Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis. J Clin Oncol 34, 3204\u20133212, https:\/\/doi.org\/10.1200\/JCO.2015.66.3955 (2016).","journal-title":"J Clin Oncol"},{"key":"19004_CR3","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1183\/16000617.0063-2016","volume":"25","author":"AC Bibby","year":"2016","unstructured":"Bibby, A. C. et al. Malignant pleural mesothelioma: an update on investigation, diagnosis and treatment. Eur Respir Rev 25, 472\u2013486, https:\/\/doi.org\/10.1183\/16000617.0063-2016 (2016).","journal-title":"Eur Respir Rev"},{"key":"19004_CR4","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1517\/14656566.2013.802774","volume":"14","author":"C Genova","year":"2013","unstructured":"Genova, C. et al. Pemetrexed for the treatment of non-small cell lung cancer. Expert Opin Pharmacother 14, 1545\u20131558, https:\/\/doi.org\/10.1517\/14656566.2013.802774 (2013).","journal-title":"Expert Opin Pharmacother"},{"key":"19004_CR5","doi-asserted-by":"publisher","first-page":"293","DOI":"10.2217\/fon.12.14","volume":"8","author":"F Grosso","year":"2012","unstructured":"Grosso, F. & Scagliotti, G. V. Systemic treatment of malignant pleural mesothelioma. Future Oncol 8, 293\u2013305, https:\/\/doi.org\/10.2217\/fon.12.14 (2012).","journal-title":"Future Oncol"},{"key":"19004_CR6","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1200\/JCO.2012.43.7459","volume":"31","author":"DE Gerber","year":"2013","unstructured":"Gerber, D. E. & Schiller, J. H. Maintenance chemotherapy for advanced non-small-cell lung cancer: new life for an old idea. J Clin Oncol 31, 1009\u20131020, https:\/\/doi.org\/10.1200\/JCO.2012.43.7459 (2013).","journal-title":"J Clin Oncol"},{"key":"19004_CR7","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.drup.2013.05.001","volume":"16","author":"M Garofalo","year":"2013","unstructured":"Garofalo, M. & Croce, C. M. MicroRNAs as therapeutic targets in chemoresistance. Drug Resist Updat 16, 47\u201359, https:\/\/doi.org\/10.1016\/j.drup.2013.05.001 (2013).","journal-title":"Drug Resist Updat"},{"key":"19004_CR8","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.2174\/13894501113149990183","volume":"14","author":"L Hong","year":"2013","unstructured":"Hong, L., Yang, Z., Ma, J. & Fan, D. Function of miRNA in controlling drug resistance of human cancers. Curr Drug Targets 14, 1118\u20131127 (2013).","journal-title":"Curr Drug Targets"},{"key":"19004_CR9","doi-asserted-by":"publisher","first-page":"e13534","DOI":"10.1371\/journal.pone.0013534","volume":"5","author":"ER Gamazon","year":"2010","unstructured":"Gamazon, E. R. et al. Exprtarget: an integrative approach to predicting human microRNA targets. PloS one 5, e13534, https:\/\/doi.org\/10.1371\/journal.pone.0013534 (2010).","journal-title":"PloS one"},{"key":"19004_CR10","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1038\/ng.2653","volume":"45","author":"GT Consortium","year":"2013","unstructured":"Consortium, G. T. The Genotype-Tissue Expression (GTEx) project. Nature genetics 45, 580\u2013585, https:\/\/doi.org\/10.1038\/ng.2653 (2013).","journal-title":"Nature genetics"},{"key":"19004_CR11","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1126\/science.1262110","volume":"348","author":"GT Consortium","year":"2015","unstructured":"Consortium, G. T. Human genomics. The Genotype-Tissue Expression (GTEx) pilot analysis: multitissue gene regulation in humans. Science 348, 648\u2013660, https:\/\/doi.org\/10.1126\/science.1262110 (2015).","journal-title":"Science"},{"key":"19004_CR12","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1038\/nature24277","volume":"550","author":"GT Consortium","year":"2017","unstructured":"Consortium, G. T. et al. Genetic effects on gene expression across human tissues. Nature 550, 204\u2013213, https:\/\/doi.org\/10.1038\/nature24277 (2017).","journal-title":"Nature"},{"key":"19004_CR13","doi-asserted-by":"publisher","first-page":"e1001273","DOI":"10.1371\/journal.pgen.1001273","volume":"7","author":"EJ Rossin","year":"2011","unstructured":"Rossin, E. J. et al. Proteins encoded in genomic regions associated with immune-mediated disease physically interact and suggest underlying biology. PLoS Genet 7, e1001273, https:\/\/doi.org\/10.1371\/journal.pgen.1001273 (2011).","journal-title":"PLoS Genet"},{"key":"19004_CR14","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.ejphar.2012.08.008","volume":"696","author":"AL Hammons","year":"2012","unstructured":"Hammons, A. L. et al. Pemetrexed alters folate phenotype and inflammatory profile in EA.hy 926 cells grown under low-folate conditions. Eur J Pharmacol 696, 12\u201317, https:\/\/doi.org\/10.1016\/j.ejphar.2012.08.008 (2012).","journal-title":"Eur J Pharmacol"},{"key":"19004_CR15","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1126\/science.288.5468.1053","volume":"288","author":"E Oda","year":"2000","unstructured":"Oda, E. et al. Noxa, a BH3-only member of the Bcl-2 family and candidate mediator of p53-induced apoptosis. Science 288, 1053\u20131058 (2000).","journal-title":"Science"},{"key":"19004_CR16","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1016\/j.molcel.2010.11.035","volume":"40","author":"XH Lowman","year":"2010","unstructured":"Lowman, X. H. et al. The proapoptotic function of Noxa in human leukemia cells is regulated by the kinase Cdk5 and by glucose. Mol Cell 40, 823\u2013833, https:\/\/doi.org\/10.1016\/j.molcel.2010.11.035 (2010).","journal-title":"Mol Cell"},{"key":"19004_CR17","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1007\/s11010-010-0683-3","volume":"350","author":"B Brodska","year":"2011","unstructured":"Brodska, B., Otevrelova, P. & Holoubek, A. Decitabine-induced apoptosis is derived by Puma and Noxa induction in chronic myeloid leukemia cell line as well as in PBL and is potentiated by SAHA. Mol Cell Biochem 350, 71\u201380, https:\/\/doi.org\/10.1007\/s11010-010-0683-3 (2011).","journal-title":"Mol Cell Biochem"},{"key":"19004_CR18","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1158\/0008-5472.CAN-12-3709","volume":"73","author":"A Vazquez","year":"2013","unstructured":"Vazquez, A., Tedeschi, P. M. & Bertino, J. R. Overexpression of the mitochondrial folate and glycine-serine pathway: a new determinant of methotrexate selectivity in tumors. Cancer Res 73, 478\u2013482, https:\/\/doi.org\/10.1158\/0008-5472.CAN-12-3709 (2013).","journal-title":"Cancer Res"},{"key":"19004_CR19","doi-asserted-by":"publisher","first-page":"1743","DOI":"10.1101\/gr.221077.117","volume":"27","author":"P Geeleher","year":"2017","unstructured":"Geeleher, P. et al. Discovering novel pharmacogenomic biomarkers by imputing drug response in cancer patients from large genomics studies. Genome research 27, 1743\u20131751, https:\/\/doi.org\/10.1101\/gr.221077.117 (2017).","journal-title":"Genome research"},{"key":"19004_CR20","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1038\/ng.3367","volume":"47","author":"ER Gamazon","year":"2015","unstructured":"Gamazon, E. R. et al. A gene-based association method for mapping traits using reference transcriptome data. Nature genetics 47, 1091\u20131098, https:\/\/doi.org\/10.1038\/ng.3367 (2015).","journal-title":"Nature genetics"},{"key":"19004_CR21","doi-asserted-by":"publisher","first-page":"E1","DOI":"10.1038\/nature19838","volume":"540","author":"P Geeleher","year":"2016","unstructured":"Geeleher, P., Gamazon, E. R., Seoighe, C., Cox, N. J. & Huang, R. S. Consistency in large pharmacogenomic studies. Nature 540, E1\u2013E2, https:\/\/doi.org\/10.1038\/nature19838 (2016).","journal-title":"Nature"},{"key":"19004_CR22","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1093\/hmg\/ddr583","volume":"21","author":"Y Wen","year":"2012","unstructured":"Wen, Y. et al. An eQTL-based method identifies CTTN and ZMAT3 as pemetrexed susceptibility markers. Human molecular genetics 21, 1470\u20131480, https:\/\/doi.org\/10.1093\/hmg\/ddr583 (2012).","journal-title":"Human molecular genetics"},{"key":"19004_CR23","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1038\/nature02168","volume":"426","author":"C HapMap","year":"2003","unstructured":"HapMap, C. The International HapMap Project. Nature 426, 789\u2013796, https:\/\/doi.org\/10.1038\/nature02168 (2003). International.","journal-title":"Nature"},{"key":"19004_CR24","doi-asserted-by":"publisher","first-page":"3963","DOI":"10.1093\/hmg\/ddi420","volume":"14","author":"T Pastinen","year":"2005","unstructured":"Pastinen, T. et al. Mapping common regulatory variants to human haplotypes. Hum Mol Genet 14, 3963\u20133971, https:\/\/doi.org\/10.1093\/hmg\/ddi420 (2005).","journal-title":"Hum Mol Genet"},{"key":"19004_CR25","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1016\/j.ajhg.2008.03.006","volume":"82","author":"S Duan","year":"2008","unstructured":"Duan, S. et al. Genetic architecture of transcript-level variation in humans. Am J Hum Genet 82, 1101\u20131113, https:\/\/doi.org\/10.1016\/j.ajhg.2008.03.006 (2008).","journal-title":"Am J Hum Genet"},{"key":"19004_CR26","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1038\/ng1955","volume":"39","author":"RS Spielman","year":"2007","unstructured":"Spielman, R. S. et al. Common genetic variants account for differences in gene expression among ethnic groups. Nat Genet 39, 226\u2013231, https:\/\/doi.org\/10.1038\/ng1955 (2007).","journal-title":"Nat Genet"},{"key":"19004_CR27","doi-asserted-by":"publisher","first-page":"55","DOI":"10.2217\/pgs.11.121","volume":"13","author":"HE Wheeler","year":"2012","unstructured":"Wheeler, H. E. & Dolan, M. E. Lymphoblastoid cell lines in pharmacogenomic discovery and clinical translation. Pharmacogenomics 13, 55\u201370, https:\/\/doi.org\/10.2217\/pgs.11.121 (2012).","journal-title":"Pharmacogenomics"},{"key":"19004_CR28","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1124\/pr.109.001461","volume":"61","author":"M Welsh","year":"2009","unstructured":"Welsh, M. et al. Pharmacogenomic discovery using cell-based models. Pharmacol Rev 61, 413\u2013429, https:\/\/doi.org\/10.1124\/pr.109.001461 (2009).","journal-title":"Pharmacol Rev"},{"key":"19004_CR29","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1158\/0008-5472.CAN-16-1476","volume":"77","author":"R Gustafsson","year":"2017","unstructured":"Gustafsson, R. et al. Crystal Structure of the Emerging Cancer Target MTHFD2 in Complex with a Substrate-Based Inhibitor. Cancer Res 77, 937\u2013948, https:\/\/doi.org\/10.1158\/0008-5472.CAN-16-1476 (2017).","journal-title":"Cancer Res"},{"key":"19004_CR30","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms4128","volume":"5","author":"R Nilsson","year":"2014","unstructured":"Nilsson, R. et al. Metabolic enzyme expression highlights a key role for MTHFD2 and the mitochondrial folate pathway in cancer. Nat Commun 5, 3128, https:\/\/doi.org\/10.1038\/ncomms4128 (2014).","journal-title":"Nat Commun"},{"key":"19004_CR31","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1038\/nrc.2016.81","volume":"16","author":"M Yang","year":"2016","unstructured":"Yang, M. & Vousden, K. H. Serine and one-carbon metabolism in cancer. Nat Rev Cancer 16, 650\u2013662, https:\/\/doi.org\/10.1038\/nrc.2016.81 (2016).","journal-title":"Nat Rev Cancer"},{"key":"19004_CR32","doi-asserted-by":"publisher","first-page":"163","DOI":"10.2478\/raon-2013-0086","volume":"48","author":"K Goricar","year":"2014","unstructured":"Goricar, K., Kovac, V. & Dolzan, V. Polymorphisms in folate pathway and pemetrexed treatment outcome in patients with malignant pleural mesothelioma. Radiol Oncol 48, 163\u2013172, https:\/\/doi.org\/10.2478\/raon-2013-0086 (2014).","journal-title":"Radiol Oncol"},{"key":"19004_CR33","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1158\/1535-7163.MCT-13-0649","volume":"13","author":"DM Moran","year":"2014","unstructured":"Moran, D. M. et al. KRAS mutation status is associated with enhanced dependency on folate metabolism pathways in non-small cell lung cancer cells. Mol Cancer Ther 13, 1611\u20131624, https:\/\/doi.org\/10.1158\/1535-7163.MCT-13-0649 (2014).","journal-title":"Mol Cancer Ther"},{"key":"19004_CR34","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1016\/j.bbabio.2011.03.010","volume":"1807","author":"IR Indran","year":"2011","unstructured":"Indran, I. R., Tufo, G., Pervaiz, S. & Brenner, C. Recent advances in apoptosis, mitochondria and drug resistance in cancer cells. Biochim Biophys Acta 1807, 735\u2013745, https:\/\/doi.org\/10.1016\/j.bbabio.2011.03.010 (2011).","journal-title":"Biochim Biophys Acta"},{"key":"19004_CR35","doi-asserted-by":"publisher","first-page":"4955","DOI":"10.1158\/0008-5472.CAN-11-0898","volume":"71","author":"MD Bareford","year":"2011","unstructured":"Bareford, M. D. et al. Sorafenib enhances pemetrexed cytotoxicity through an autophagy-dependent mechanism in cancer cells. Cancer Res 71, 4955\u20134967, https:\/\/doi.org\/10.1158\/0008-5472.CAN-11-0898 (2011).","journal-title":"Cancer Res"},{"key":"19004_CR36","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1093\/jnci\/92.13.1042","volume":"92","author":"P Costantini","year":"2000","unstructured":"Costantini, P., Jacotot, E., Decaudin, D. & Kroemer, G. Mitochondrion as a novel target of anticancer chemotherapy. J Natl Cancer Inst 92, 1042\u20131053 (2000).","journal-title":"J Natl Cancer Inst"},{"key":"19004_CR37","doi-asserted-by":"publisher","first-page":"3475","DOI":"10.3892\/or.2017.5624","volume":"37","author":"GJ Li","year":"2017","unstructured":"Li, G. J. et al. Effect of miR-1244 on cisplatin-treated non-small cell lung cancer via MEF2D expression. Oncology reports 37, 3475\u20133483, https:\/\/doi.org\/10.3892\/or.2017.5624 (2017).","journal-title":"Oncology reports"},{"key":"19004_CR38","doi-asserted-by":"publisher","first-page":"16570","DOI":"10.1073\/pnas.1207917109","volume":"109","author":"G Romano","year":"2012","unstructured":"Romano, G. et al. MiR-494 is regulated by ERK1\/2 and modulates TRAIL-induced apoptosis in non-small-cell lung cancer through BIM down-regulation. Proceedings of the National Academy of Sciences of the United States of America 109, 16570\u201316575, https:\/\/doi.org\/10.1073\/pnas.1207917109 (2012).","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"19004_CR39","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1038\/sj.cdd.4401554","volume":"12","author":"R Li","year":"2005","unstructured":"Li, R., Moudgil, T., Ross, H. J. & Hu, H. M. Apoptosis of non-small-cell lung cancer cell lines after paclitaxel treatment involves the BH3-only proapoptotic protein Bim. Cell death and differentiation 12, 292\u2013303, https:\/\/doi.org\/10.1038\/sj.cdd.4401554 (2005).","journal-title":"Cell death and differentiation"},{"key":"19004_CR40","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1097\/JTO.0000000000000535","volume":"10","author":"JY Lee","year":"2015","unstructured":"Lee, J. Y. et al. The BIM Deletion Polymorphism and its Clinical Implication in Patients with EGFR-Mutant Non-Small-Cell Lung Cancer Treated with EGFR Tyrosine Kinase Inhibitors. Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer 10, 903\u2013909, https:\/\/doi.org\/10.1097\/JTO.0000000000000535 (2015).","journal-title":"Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer"},{"key":"19004_CR41","doi-asserted-by":"publisher","first-page":"25696","DOI":"10.18632\/oncotarget.4678","volume":"6","author":"W Nie","year":"2015","unstructured":"Nie, W., Tao, X., Wei, H., Chen, W. S. & Li, B. The BIM deletion polymorphism is a prognostic biomarker of EGFR-TKIs response in NSCLC: A systematic review and meta-analysis. Oncotarget 6, 25696\u201325700, https:\/\/doi.org\/10.18632\/oncotarget.4678 (2015).","journal-title":"Oncotarget"},{"key":"19004_CR42","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1038\/nm.2713","volume":"18","author":"KP Ng","year":"2012","unstructured":"Ng, K. P. et al. A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer. Nature medicine 18, 521\u2013528, https:\/\/doi.org\/10.1038\/nm.2713 (2012).","journal-title":"Nature medicine"},{"key":"19004_CR43","doi-asserted-by":"publisher","first-page":"1868","DOI":"10.1002\/jcp.22517","volume":"226","author":"MY Shah","year":"2011","unstructured":"Shah, M. Y., Pan, X., Fix, L. N., Farwell, M. A. & Zhang, B. 5-Fluorouracil drug alters the microRNA expression profiles in MCF-7 breast cancer cells. J Cell Physiol 226, 1868\u20131878, https:\/\/doi.org\/10.1002\/jcp.22517 (2011).","journal-title":"J Cell Physiol"},{"key":"19004_CR44","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1016\/j.biopha.2014.09.011","volume":"68","author":"J Lv","year":"2014","unstructured":"Lv, J. et al. miRNA expression patterns in chemoresistant breast cancer tissues. Biomed Pharmacother 68, 935\u2013942, https:\/\/doi.org\/10.1016\/j.biopha.2014.09.011 (2014).","journal-title":"Biomed Pharmacother"},{"key":"19004_CR45","doi-asserted-by":"publisher","first-page":"2061","DOI":"10.1002\/jcb.25162","volume":"116","author":"E Tormo","year":"2015","unstructured":"Tormo, E. et al. MicroRNA Profile in Response to Doxorubicin Treatment in Breast Cancer. J Cell Biochem 116, 2061\u20132073, https:\/\/doi.org\/10.1002\/jcb.25162 (2015).","journal-title":"J Cell Biochem"},{"key":"19004_CR46","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1177\/1933719112459220","volume":"20","author":"NH Phuah","year":"2013","unstructured":"Phuah, N. H. et al. Alterations of microRNA expression patterns in human cervical carcinoma cells (Ca Ski) toward 1\u2032S-1\u2032-acetoxychavicol acetate and cisplatin. Reprod Sci 20, 567\u2013578, https:\/\/doi.org\/10.1177\/1933719112459220 (2013).","journal-title":"Reprod Sci"},{"key":"19004_CR47","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.3892\/or.2011.1381","volume":"26","author":"R Hummel","year":"2011","unstructured":"Hummel, R. et al. Chemotherapy-induced modification of microRNA expression in esophageal cancer. Oncol Rep 26, 1011\u20131017, https:\/\/doi.org\/10.3892\/or.2011.1381 (2011).","journal-title":"Oncol Rep"},{"key":"19004_CR48","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1038\/bjc.2014.652","volume":"112","author":"TF Hansen","year":"2015","unstructured":"Hansen, T. F., Carlsen, A. L., Heegaard, N. H., Sorensen, F. B. & Jakobsen, A. Changes in circulating microRNA-126 during treatment with chemotherapy and bevacizumab predicts treatment response in patients with metastatic colorectal cancer. Br J Cancer 112, 624\u2013629, https:\/\/doi.org\/10.1038\/bjc.2014.652 (2015).","journal-title":"Br J Cancer"},{"key":"19004_CR49","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1007\/s00280-007-0500-1","volume":"61","author":"GJ Gordon","year":"2008","unstructured":"Gordon, G. J. et al. Preclinical studies of the proteasome inhibitor bortezomib in malignant pleural mesothelioma. Cancer Chemother Pharmacol 61, 549\u2013558, https:\/\/doi.org\/10.1007\/s00280-007-0500-1 (2008).","journal-title":"Cancer Chemother Pharmacol"},{"key":"19004_CR50","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1038\/sj.cgt.7701029","volume":"14","author":"J Neukirchen","year":"2007","unstructured":"Neukirchen, J. et al. The proteasome inhibitor bortezomib acts differently in combination with p53 gene transfer or cytotoxic chemotherapy on NSCLC cells. Cancer Gene Ther 14, 431\u2013439, https:\/\/doi.org\/10.1038\/sj.cgt.7701029 (2007).","journal-title":"Cancer Gene Ther"},{"key":"19004_CR51","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1016\/j.lungcan.2009.07.011","volume":"68","author":"GV Scagliotti","year":"2010","unstructured":"Scagliotti, G. V. et al. A randomized phase II study of bortezomib and pemetrexed, in combination or alone, in patients with previously treated advanced non-small-cell lung cancer. Lung Cancer 68, 420\u2013426, https:\/\/doi.org\/10.1016\/j.lungcan.2009.07.011 (2010).","journal-title":"Lung Cancer"},{"key":"19004_CR52","doi-asserted-by":"publisher","DOI":"10.1186\/1476-4598-13-230","volume":"13","author":"D Del Bufalo","year":"2014","unstructured":"Del Bufalo, D. et al. Histone deacetylase inhibition synergistically enhances pemetrexed cytotoxicity through induction of apoptosis and autophagy in non-small cell lung cancer. Mol Cancer 13, 230, https:\/\/doi.org\/10.1186\/1476-4598-13-230 (2014).","journal-title":"Mol Cancer"},{"key":"19004_CR53","doi-asserted-by":"publisher","first-page":"2818","DOI":"10.1158\/1078-0432.CCR-08-1579","volume":"15","author":"F Vandermeers","year":"2009","unstructured":"Vandermeers, F. et al. Valproate, in combination with pemetrexed and cisplatin, provides additional efficacy to the treatment of malignant mesothelioma. Clin Cancer Res 15, 2818\u20132828, https:\/\/doi.org\/10.1158\/1078-0432.CCR-08-1579 (2009).","journal-title":"Clin Cancer Res"},{"key":"19004_CR54","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.18632\/oncotarget.13640","volume":"8","author":"L Booth","year":"2017","unstructured":"Booth, L., Roberts, J. L., Poklepovic, A., Gordon, S. & Dent, P. PDE5 inhibitors enhance the lethality of pemetrexed through inhibition of multiple chaperone proteins and via the actions of cyclic GMP and nitric oxide. Oncotarget 8, 1449\u20131468, https:\/\/doi.org\/10.18632\/oncotarget.13640 (2017).","journal-title":"Oncotarget"},{"key":"19004_CR55","doi-asserted-by":"publisher","first-page":"4337","DOI":"10.1158\/1078-0432.CCR-15-0133","volume":"21","author":"M Komatsu","year":"2015","unstructured":"Komatsu, M. et al. Pharmacoethnicity in Paclitaxel-Induced Sensory Peripheral Neuropathy. Clin Cancer Res 21, 4337\u20134346, https:\/\/doi.org\/10.1158\/1078-0432.CCR-15-0133 (2015).","journal-title":"Clin Cancer Res"},{"key":"19004_CR56","doi-asserted-by":"publisher","first-page":"e47","DOI":"10.1093\/nar\/gkv007","volume":"43","author":"ME Ritchie","year":"2015","unstructured":"Ritchie, M. E. et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res 43, e47, https:\/\/doi.org\/10.1093\/nar\/gkv007 (2015).","journal-title":"Nucleic Acids Res"},{"key":"19004_CR57","doi-asserted-by":"publisher","DOI":"10.1186\/gb-2003-4-5-p3","volume":"4","author":"G Dennis Jr.","year":"2003","unstructured":"Dennis, G. Jr. et al. DAVID: Database for Annotation, Visualization, and Integrated Discovery. Genome Biol 4, P3 (2003).","journal-title":"Genome Biol"},{"key":"19004_CR58","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1038\/nbt1295","volume":"25","author":"K Lage","year":"2007","unstructured":"Lage, K. et al. A human phenome-interactome network of protein complexes implicated in genetic disorders. Nat Biotechnol 25, 309\u2013316, https:\/\/doi.org\/10.1038\/nbt1295 (2007).","journal-title":"Nat Biotechnol"},{"key":"19004_CR59","doi-asserted-by":"publisher","first-page":"3734","DOI":"10.1073\/pnas.80.12.3734","volume":"80","author":"CJ Edgell","year":"1983","unstructured":"Edgell, C. J., McDonald, C. C. & Graham, J. B. Permanent cell line expressing human factor VIII-related antigen established by hybridization. Proc Natl Acad Sci USA 80, 3734\u20133737 (1983).","journal-title":"Proc Natl Acad Sci USA"},{"key":"19004_CR60","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1002\/gepi.21808","volume":"38","author":"HE Wheeler","year":"2014","unstructured":"Wheeler, H. E. et al. Poly-omic prediction of complex traits: OmicKriging. Genetic epidemiology 38, 402\u2013415, https:\/\/doi.org\/10.1002\/gepi.21808 (2014).","journal-title":"Genetic epidemiology"},{"key":"19004_CR61","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","volume":"2","author":"E Cerami","year":"2012","unstructured":"Cerami, E. et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov 2, 401\u2013404, https:\/\/doi.org\/10.1158\/2159-8290.CD-12-0095 (2012).","journal-title":"Cancer Discov"},{"key":"19004_CR62","doi-asserted-by":"crossref","unstructured":"Hastie, T., Tibshirani, R. & Wainwright, M. Statistical learning with sparsity: the lasso and generalizations. CRC press, 2015.","DOI":"10.1201\/b18401"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-19004-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-19004-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-19004-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,21]],"date-time":"2022-12-21T01:01:40Z","timestamp":1671584500000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-19004-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1,15]]},"references-count":62,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2018,12]]}},"alternative-id":["19004"],"URL":"https:\/\/doi.org\/10.1038\/s41598-017-19004-3","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,1,15]]},"assertion":[{"value":"12 July 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 December 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 January 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"733"}}